For Physicians, Pharma, and research
We develop reliable blood-based diagnostics that provide quick, objective, and economical detection of mental health conditions.
First study (87 patients, Univ. Greifswald) showed 90% specificity and 99% NPV & international patent submitted.
A 500-patient validation study started, aiming to confirm accuracy, assess differential diagnosis, and enable monitoring.
Launch planned for early 2027, bringing clinically validated technology into real-world practice.
Explore how we can bring direct value to your individual needs
Provides biologically derived information intended to complement clinical evaluation and professional judgment.
Supports consistent assessment processes across increasing patient volumes.
Designed to fit within existing diagnostic and referral pathways without adding unnecessary administrative burden.
Up to 80% are undiagnosed due to long waiting time and limited capacity
Skip long diagnostic delays — get results faster and start your personalized care without months of uncertainty.
Early diagnosis helps boost focus, confidence, and relationships, turning challenges into opportunities for a balanced life.
Improve patient selection by adding biological markers, better stratification of subcohorts.
Facilitates more standardized cohort definition in observational studies and clinical trials.
Starting with ADHD, expanding to additional mental health conditions over time.
Cost Reduction Support patients in getting an accurate diagnosis, helping to reduce overall healthcare costs, while enabling continuous monitoring and enhancing treatment effectiveness.
Enable better cost and risk estimation through objective, data-driven diagnostics.
Identify high-risk patients earlier and allocate healthcare resources more effectively.
Diagnoses ADHD using eight identified metabolomic biomarkers in the blood
93% Accurate, 5 days TAT & Price ~ €239 per test.
Pain-free blood sampling device – proven and already used in practice.
